- Research article
- Open Access
The role of MCP-1-CCR2 ligand-receptor axis in chondrocyte degradation and disease progress in knee osteoarthritis
© Xu et al. 2015
- Received: 13 August 2015
- Accepted: 4 November 2015
- Published: 17 November 2015
Osteoarthritis (OA) is a common arthritic disease and multifactorial whole-joint disease. Interactions of chemokines and OA is inadequately documented.
In vivo and in vitro studies were conducted to investigate monocyte chemoattractant protein 1 (MCP-1) and receptor chemokine (C–C motif) receptor 2 (CCR2) in chondrocyte degradation and cartilage degeneration. Chondrocytes from 16 OA patients and 6 normal controls were involved in this study. After stimulation of MCP-1, the expression of MCP-1 and CCR2 increased significantly (P < 0.001) and the expression of MMP-13 also increased (P < 0.05). MCP-1 stimulation also induced (or enhanced) the apoptosis of OA chondrocytes (P < 0.05). Additionally, the degradation of cartilage matrix markers (metalloproteinase 3 and 13, MMP3 and MMP13) in the culture medium of normal chondrocytes was also assessed. Furthermore, intra-articular injection of MCP-1 in mouse knees induced cartilage degradation and the CCR2 antagonist did not impede cartilage destroy in rats knees of monosodium iodoacetate (MIA) model.
The results of this study demonstrate that the MCP-1-CCR2 ligand-receptor axis plays a special role in the initiation and progression of OA pathology. Patients with ambiguous etiology can gain some insight from the MCP-1-CCR2 ligand-receptor axis.
OA is a common arthritic disease and multifactorial whole-joint disease. It has been recently redefined as a disease that affects the whole joint, including cellular changes, structural defects and dysfunction of all the joint compartments, e.g. cartilage, bone and synovium, the etiology of the disease is not completely defined [1–3]. Despite its widespread occurrence in the aged population, the pathogenesis of OA remains largely unknown.
The normal balance between synthesis and degradation of the cartilage matrix is biased toward degradation, and it has been shown that cytokines such as interleukin-1 (IL-1), chemokines like the C–C class of the beta chemokine family and tumor necrosis factor (TNF), as well as functional changes of the chondrocytes themselves, play major roles in the process of deterioration by inducing expression of proteinases, such as those of the MMP family. MCP-1 is a member of the C–C class of the beta chemokine family and one of the key factors involved in the initiation of inflammation. It triggers chemotaxis and transendothelial migration of monocytes to inflammatory lesions by interacting with the membrane CCR2 in monocytes . MCP-1 is secreted by fibroblasts, endothelial cells, vascular smooth muscle cells, monocytes, T cells, and other cell types that mediate or are involved in the influx of cells to and at sites of inflammation . MCP-1 expression has been observed in a large number of tissues during inflammation-dependent disease progression, including atherosclerosis , arthritis  and cancer .
As shown in early studies, OA is characterized by the degradation of cartilage, as the main (or unique) cell in cartilage; the chondrocyte plays an important role in cartilage degeneration and OA disease pathology [8–10]. We hypothesized that, despite the cytokines, the chemokines alone may also mediate certain independent interactions with chondrocytes and play a role in the pathology of OA. In this study, we investigated the interaction between MCP-1 and chondrocytes and the possible role of MCP-1-CCR2 ligand-receptor axis in cartilage degradation and disease progression in osteoarthritis.
The expression of MCP-1-CCR2 axis genes and cartilage matrix markers after stimulation of MCP-1
We measured the level of chemokine protein MCP-1 secreted by chondrocytes in response to MCP-1 itself in OA and wild-type (normal controls) chondrocytes. Three days after stimulation of MCP-1 in chondrocytes from OA patients, detectable amounts of MCP-1 protein were observed and the expression of MCP-1 was higher in stimulated samples than in unstimulated controls in each pair of groups (Fig. 1e). While both MMP3 and MMP13 levels were elevated in response to MCP-1 stimulation in MCP-1 stimulated wild-type chondrocytes (N–M group) compared with unstimulated wild-type chondrocytes (N–N group), only MMP13 reached statistical significance (P < 0.05) (Fig. 1f, g).
Chondrocyte apoptosis assessment and the expression of CCR2 in OA chondrocytes
Micro-CT analysis of subchondral bone changes in rats
The parameter of micro-CT analysis of the rats knees (each pair of subgroup n = 6)
52.7 ± 6.8
17.825 ± 1.741
0.113 ± 0.011
4.651 ± 0.221
0.102 ± 0.019
53.2 ± 4.9
17.512 ± 1.500
0.115 ± 0.010
4.635 ± 0.242
0.101 ± 0.014
71.5 ± 5.4
11.585 ± 1.220
0.174 ± 0.019
4.113 ± 0.151
0.069 ± 0.011
74.5 ± 4.3
11.028 ± 0.967
0.183 ± 0.017
4.089 ± 0.170
0.062 ± 0.009
53.1 ± 5.1
18.411 ± 1.733
0.109 ± 0.011
4.855 ± 0.289
0.097 ± 0.013
53.6 ± 6.1
18.884 ± 2.003
0.107 ± 0.011
5.000 ± 0.112
0.093 ± 0.014
75.6 ± 4.8
11.108 ± 1.016
0.181 ± 0.017
4.180 ± 0.177
0.058 ± 0.011
76.1 ± 6.0
11.274 ± 1.178
0.179 ± 0.018
4.262 ± 0.120
0.056 ± 0.013
Femoral condyle and tibial
52.6 ± 5.7
18.092 ± 1.568
9.506 ± 0.481
53.4 ± 5.0
17.963 ± 1.365
9.634 ± 0.295
73.9 ± 5.4
11.233 ± 1.165
8.293 ± 0.322
75.1 ± 4.8
11.117 ± 0.999
8.351 ± 0.272
78.0 ± 8.4
28.159 ± 41.708
0.159 ± 0.079
4.291 ± 0.552
0.047 ± 0.024
80.6 ± 7.1
9.702 ± 2.143
0.214 ± 0.043
3.847 ± 0.481
0.049 ± 0.012
89.4 ± 4.3
6.944 ± 1.695
0.305 ± 0.083
3.074 ± 0.614
0.033 ± 0.008
89.4 ± 2.2
24.565 ± 43.152
0.244 ± 0.113
10.852 ± 18.961
0.028 ± 0.013
Joint pathology scores in mice and rats
Despite the widespread prevalence of OA, its etiology is still unknown. Currently, known OA risk factors are not fully and clear accordant with the clinical OA etiologies. There have been many previous studies focused on the roles of cytokines and chemokines in the pathological process of OA .
MCP-1 is one of the chemokines which is involved in osteoarthritis, the ligand is CCR2. MCP-1 is believed to play a key role in the inflammation process . Whether OA is caused by inflammatory changes or simply because the biomechanics of human joint abnormalities is contentious at present . However,the classification of OA as a kind of arthritis and having some inflammation in joints is without much argument. Whether systemic or localized inflammation in focal joints is strongly associated with the origination and severity of OA, especially in those patients with normal joint mechanism, without previous trauma in/near focal joints, and with the exclusion of other risk factors, cannot be easily recognized. The role of MCP-1 in focal joints as risk factor of OA was unconfirmed. Our work focused on the role of MCP-1 as a key mediator of focal, not systemic, inflammation .
In our present study, we confirmed that MCP-1 operates in a positive feedback mechanism in wild-type (normal controls) and OA chondrocytes. Our experiments showed that increased MCP-1 promoted apoptosis while simultaneously inhibiting the proliferation of wild-type (normal controls) and OA cartilage cells under normal culture conditions. From our quantitative data, we determined that elevated MCP-1 levels promoted the pathogenesis of OA more so than other joint disorders, such as RA. Furthermore, we observed that an increase in MCP-1 levels in our culture system also resulted in an increase in its ligand, CCR2. Additionally, the stimulation of MCP-1 expression in wild-type (normal controls) chondrocytes resulted in the increased expression of degeneration proteins, MMP3 and MMP13, suggesting that MCP-1 attracted macrophages and other inflammatory cells to the joint and elicited an effect on cartilage cells at the same time. Through the results in our present study, we speculate that MCP-1 expedites the damage of cartilage by enhancing the apoptosis of chondrocytes while inhibiting their proliferation. Furthermore, we believe that MCP-1 induced degenerative changes in wild-type (normal controls) cartilage cells under our culture conditions.
Similar to our cell culture experiments, we observed inflammation and cartilage damage in our in vivo study after intra articular injection (IA) of MCP-1 in the knee joints of mice. The joint pathology changes induced by MCP-1 were significantly worse compared to the contralateral control injected knees. We hypothesized that treatment of an MIA rat model with a CCR2 antagonist would improve the OA observed. However, we observed no significant improvement in the pathology scores in rats and the micro CT analysis in the whole knee joint was insignificant. While we confirmed the destructive effects of MIA injection into knee joints, we encountered setbacks with intra-articular injection. Aggressive subchondral bone lesions form the basis for macroscopic evaluation [19, 20]. We would keep focus on developing structure-modifying treatments (disease-modifying OA drugs) by focusing on the CCR2 antagonist. Since there had been successful endeavors in system research of animal studies .
Modeling OA for research is rather complicated. While age has been confirmed to be a risk factor of OA; presently, we lack a suitable marker for diagnosis of OA disease . Elevated levels of chemokines in serum in elderly individuals have been observed  and to quantify the degree of MCP-1 and CCR2 increase in human tissue samples, we used samples from younger, unaffected patients as a control. It is possible that we have underestimated the degree of MCP-1 increase in elderly patients with OA since our control samples were obtained from tumor patients and MCP-1 is overexpressed in many tumors .
Taken together, the present study suggests that MCP-1 induces the degradation of wild-type (normal controls) and OA chondrocytes. These effects were embodied in the inhibition of proliferation, induction of degeneration and apoptosis of the wild-type (normal controls) and OA chondrocytes. The damaging effects of MCP-1 on cartilage cells may be due to a positive feedback mechanism. Based on the results of our present study, we infer that MCP-1 has a special role in the pathogenesis of OA and requires further investigation to delineate the MCP-1 pathway.
Articular cartilage and synovial membrane specimens were obtained from 18 OA (mean age 38 years, range 18–65 years), 4 RA patients (mean age 64 years, range 48–74 years) and 6 wild-type (normal controls, mean age 43 years, range 34–53 years) who were undergoing total joint replacement at Peking University, People’s hospital, Beijing. All patients met the American College of Rheumatology criteria for OA (Altman R.1986), RA (2009 ACR/EULAR) . Wild-type (normal controls) (normal) human cartilage was collected from the tibial plateau of 6 patients with practically no evidence of knee joint destruction who were undergoing joint replacement because of femoral or pelvic malignant tumor. All samples were obtained with informed consent from the patients and the study protocol was approved by the ethics committee of Peking University People’s Hospital.
Chondrocyte and synovial fibroblast isolation
Cartilage was minced and digested by rotating overnight at 37 °C in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Life Technologies, NY, USA) containing 1 mg/ml of bacterial collagenase II (Gibco). The cells released by enzymatic digestion were filtered through a sterile nylon strainer (Coring, NY, USA), washed, and centrifuged. The pellet was seeded into the six cm diameter Petri dish (Coring) at a density of 4 × 105 cells and cultivated at 37 °C in a humidified atmosphere of 5 % CO2. The culture medium used was DMEM containing 10 % heat-inactivated fetal calf serum (Gibco), 100 units/ml penicillin (Gibco), and 100 mg/ml streptomycin (Gibco). Medium was replaced every week and cells were used between the second and third passages.
Tissues of Synovial membrane from OA and RA patients were minced and digested in DMEM containing 1 mg/ml of bacterial collagenase I (Gibco) for 3 h and then filtered and centrifuged the same as chondrocytes. The pellets was recognized as synovial fibroblasts, then seeded and cultivated at a density of 4 × 105 cells, the culture medium employed the same as chondrocytes, and cells were used between the second and third passages.
Enzyme-linked immunosorbent assay (ELISA)
After the medium was changed, cell monolayers were incubated with or without stimulation with recombinant human MCP-1 (California Bioscience, Coachella, CA) at the indicated concentrations of 20 ng/ml for 72 h. Supernatants were then collected and stored at −70 °C until used. MCP-1, collagen II and MMP3, MMP13 concentrations in the culture supernatants were evaluated with commercial ELISA kits, according to the instructions of the manufacturer. The ELISA kits for this study were as follows: MCP-1(438807, LEGEND MAX, Biolegend, San Diego, CA 92121, USA), 7.8–500 pg/ml; Collagen II (SEA572Hu, Cloud-Clone Corp. Huston, TX 77082, USA), 46.88-3000 pg/ml; MMP3 (SCA101Hu, Cloud-Clone Corp. Huston, TX 77082, USA), 41.2–60,000 pg/ml; MMP13 (SCA099Hu, Cloud-Clone Corp. Huston, TX 77082, USA). 54.9–160,000 pg/ml.
Reverse transcriptase–polymerase chain reaction (RT-PCR)
Total RNA was extracted from the chondrocytes using the single-step method (TRIzol Reagent, Invitrogen, Carlsbad, CA, USA). First-strand complementary DNA (cDNA) was synthesized in a 10-μl reaction mixture by incubation at 37 °C for 5 min. The resulting cDNA (5 μl) was subjected to PCR using SYBRGREEN (TOYOBO, OSAKA, JAPAN) and the specific primers for the chemokines, MCP-1, CCR2, collagen II and GAPDH were showed as follow: MCP-1: Sense ATAGCAGCCACCTTCATTCC, Antisense TTTCCCCAAGTCTCTGTATCT; CCR-2b: Sense GCGGAATCTTCTTCATCATCCTC, Antisense CCTCTTCTTCTCGTTTCGACACC; GAPDH: Sense CCACCCATGGCAAATTCCATGGCA, Antisense TCTAGACGGCAGGTCAGGTCCACC.
Flow cytometric analysis
We harvested and washed the cells, and resuspended the cells in 1 × annexin-binding buffer, added 5 μl Alexa Fluor 488 annexin V and 1 μl 100 μg/ml PI working solution (V13241, MOLECULAR PROBES, invitrogen, Eugene, OR 97402, USA) to each 100 μl of cell suspension and incubated the cells at room temperature for 15 min. After incubation, 400 μl 1 × annexin-binding buffer was added and gently mixed, while keeping the samples on ice. The stained cells were analyzed by flow cytometry, measuring the fluorescence emission at 530 and 570 nm using 488 nm excitation.
Protein samples were prepared by mixing sample with LDS Sample Buffer (Life Technologies, Carlsbad, CA, USA) and then boiled at 95 °C for 5 min. Proteins were separated on a NuPAGE 4–12 % Bis–Tris Gel (Life Technologies) and electro-transferred onto polyvinylidene difluoride membranes. The membranes were blocked with 5 % non-fat milk for 2 h at room temperature in Tris-buffered saline containing 0.5 % Tween-20 (TBST). The membranes were then rinsed twice with TBST and incubated with rabbit polyclonal to CCR2 (dilution of 1:2000, ab21667, Abcam, Shanghai, China) overnight at 4 °C, and then washed and incubated with corresponding goat anti-Rabbit antibody at room temperature for 1 h. Proteins were visualized via chemiluminescence with ImageQuant 350 (GE HEALTHCARE, Piscataway, NJ, USA).
Joint pathology in mice and rats
The procedures used in this study were approved by the ethics committee of Peking University People’s Hospital. Animals were provided with living conditions, food, and housing consistent with the approved animal care operating procedures.
Male Sprague–Dawley rats (175–200 g; Vital River Laboratory, Beijing China) were allowed to acclimate to the facility for 7 days. Rats were anesthetized with 10 % Chloral hydrate (H20064279, Peking University People’s Hospital) and given single intra-articular injection of 0.5 mg of MIA (Sigma, St. Louis, MO, USA) through the infrapatellar ligament of the knee. MIA was dissolved in physiologic saline and administered once in a volume of 25 µl using a 27-gauge, 0.5-inch needle in both knees. The right knee was the experimental, injected with 25 µl of CCR-2 antagonist (Sigma), with the concentration of 50 ng/ml [25, 26] once a week, for 4 weeks and the contralateral (left) knee was treated as a control knee which received an injection of physiological saline. The first injection of CCR-2 antagonist or physiological saline was given 3 days after the injection of MIA. The amount of MIA injected into the joint had been determined in a dose–response study  and we finished the intra-articulate injection of MIA in an amount of 0.25 mg/joint.
Micro-CT analysis of subchondral bone changes in rats
Prior to histological sectioning, all rat knee joints were scanned using a micro-CT system (Inveon MM system, Siemens, Munich, Germany) with the following parameters: 360 projections over 360° increment, 600 ms exposure time averaged per projection, voltage of 80 kV, current of 500 μA, voxel size of 9.08 μm, and a scan time of approximately 20 min per knee. The reconstructed data sets were examined using three-dimensional data analysis software (Inveon Research Workplace, Siemens, Munich, Germany).
Tissue samples were prepared for light microscopy using standard procedures. Briefly, samples were fixed in 10 % phosphate-buffered formalin and subsequently decalcified in 5 % formic acid for 72 h. Frontal section joints were routinely processed to HE slides and examined under the light microscope. The joint degeneration was assessed with the OARSI cartilage degeneration score in histological assessments of the rats .
Male C57Bl/6 (Vital River Laboratory) mice aged 10 weeks were used in all experiments. The right knee joints of the mice were injected once a week, for 3 weeks, intra-articularly through the patellar ligament, with a 6-μl solution of MCP-1 (CB500038, California Bioscience, Coachella, CA, USA) at a concentration of 25 ng/ml. The dissolving agent was 0.1 % BSA, according to the manufacturer. At the same time, the left control knee joint was injected with 6 μl of 0.1 % BSA. Two mice, injected with MCP-1, were sacrificed by cervical dislocation after an inhalation of ibuprofen at two time-points 21 and 42 days, after intra-articular injection. Histological assessments of knee joints in the mouse were adopted from the OARSI histopathology initiative .
Statistical analysis was performed with SPSS 21.0 (IBM SPSS, Chicago, IL, USA). Paired/unpaired t test was used to analyze significant difference between control and experimental groups. All data, including Micro CT, was presented as the mean ± SEM. P < 0.05 was considered statistically significant. The results of ELISA were assayed by regression analysis, Curve Expert professional 2.2 (Daniel G. Hyams) was used to draw the best standard curve. All the graphs were produced by Graphpad Prism 5 (GraphPad Software, La Jolla, CA, USA).
All authors have made substantial contributions to (1) the conception and design of the study, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be submitted.
The specific contributions of the authors are as follows: (1) Conception and design of the study: YK, YK-X, and JH-L, (2) Analysis and interpretation of the data: YK-X, YK, and WB, (3) Drafting of the article: YK-X, YK, BW, and JH-L, (4) Critical revision of the article for important intellectual content: YK-X, YK, and JH-L, (5) Final approval of the article: YK-X, YK, BW, and JH-L, (6) Statistical expertise: YK-X, YK, and JH-L, (7) Obtaining of funding: JH-L, (8) Collection and assembly of data: YK-X. All authors read and approved the final manuscript.
This study was supported by Beijing Municipal Science and Technology Commission (No. 2107000065) and The National Natural Science Fund (No.81441056). Thanks for the hard work of Micro-CT scan and analysis by Dr. Hao Liu, The Core Laboratory Peking University, School and Hospital of Stomatology.
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone. 2012;51(2):249–57. doi:10.1016/j.bone.2012.02.012.View ArticlePubMed CentralPubMedGoogle Scholar
- Haseeb A, Haqqi TM. Immunopathogenesis of osteoarthritis. Clin Immunol. 2013;146(3):185–96. doi:10.1016/j.clim.2012.12.011.View ArticlePubMed CentralPubMedGoogle Scholar
- Vincent TL. Targeting mechanotransduction pathways in osteoarthritis: a focus on the pericellular matrix. Curr Opin Pharmacol. 2013;13(3):449–54. doi:10.1016/j.coph.2013.01.010.View ArticlePubMedGoogle Scholar
- O’Hayre M, Salanga CL, Handel TM, Allen SJ. Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J. 2008;409(3):635–49. doi:10.1042/BJ20071493.View ArticlePubMedGoogle Scholar
- Conti P, DiGioacchino M. MCP-1 and RANTES are mediators of acute and chronic inflammation. Allerg Asthma Proc Off J Reg State Allerg Soc. 2001;22(3):133–7.View ArticleGoogle Scholar
- Shin WS, Szuba A, Rockson SG. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis. 2002;160(1):91–102.View ArticlePubMedGoogle Scholar
- Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 2000;43(1):38–47. doi:10.1002/1529-0131(200001)43:1<38:AID-ANR6>3.0.CO;2-L.View ArticlePubMedGoogle Scholar
- Findlay DM, Atkins GJ. Osteoblast-chondrocyte interactions in osteoarthritis. Current osteoporosis reports. 2014;12(1):127–34. doi:10.1007/s11914-014-0192-5.View ArticlePubMed CentralPubMedGoogle Scholar
- Flannery CR, Little CB, Hughes CE, Caterson B. Expression and activity of articular cartilage hyaluronidases. Biochem Biophys Res Commun. 1998;251(3):824–9. doi:10.1006/bbrc.1998.9561.View ArticlePubMedGoogle Scholar
- Buttle DJ, Fowles A, Ilic MZ, Handley CJ. “Aggrecanase” activity is implicated in tumour necrosis factor alpha mediated cartilage aggrecan breakdown but is not detected by an in vitro assay. Mol Pathol MP. 1997;50(3):153–9.View ArticlePubMedGoogle Scholar
- Borzi RM, Mazzetti I, Macor S, Silvestri T, Bassi A, Cattini L, et al. Flow cytometric analysis of intracellular chemokines in chondrocytes in vivo: constitutive expression and enhancement in osteoarthritis and rheumatoid arthritis. FEBS Lett. 1999;455(3):238–42.View ArticlePubMedGoogle Scholar
- Pulsatelli L, Dolzani P, Piacentini A, Silvestri T, Ruggeri R, Gualtieri G, et al. Chemokine production by human chondrocytes. J Rheumatol. 1999;26(9):1992–2001.PubMedGoogle Scholar
- Glasson SS, Chambers MG, Van Den Berg WB, Little CB. The OARSI histopathology initiative—recommendations for histological assessments of osteoarthritis in the mouse. Osteoarthr Cartil. 2010;18(Suppl 3):S17–23. doi:10.1016/j.joca.2010.05.025.View ArticlePubMedGoogle Scholar
- Gerwin N, Bendele AM, Glasson S, Carlson CS. The OARSI histopathology initiative—recommendations for histological assessments of osteoarthritis in the rat. Osteoarthr Cartil. 2010;18(Suppl 3):S24–34. doi:10.1016/j.joca.2010.05.030.View ArticlePubMedGoogle Scholar
- Wojdasiewicz P, Poniatowski LA, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm. 2014;2014:561459. doi:10.1155/2014/561459.View ArticlePubMed CentralPubMedGoogle Scholar
- Melgarejo E, Medina MA, Sanchez-Jimenez F, Urdiales JL. Monocyte chemoattractant protein-1: a key mediator in inflammatory processes. Int J Biochem Cell Biol. 2009;41(5):998–1001. doi:10.1016/j.biocel.2008.07.018.View ArticlePubMedGoogle Scholar
- Cicuttini FM, Wluka AE. Osteoarthritis: is OA a mechanical or systemic disease? Nat Rev Rheumatol. 2014;10(9):515–6. doi:10.1038/nrrheum.2014.114.View ArticlePubMedGoogle Scholar
- Bonfante HL, Almeida CS, Abramo C, Grunewald ST, Levy RA, Teixeira HC. CCL2, CXCL8, CXCL9 and CXCL10 serum levels increase with age but are not altered by treatment with hydroxychloroquine in patients with osteoarthritis of the knees. Int J Rheum Dis. 2015;. doi:10.1111/1756-185X.12589.PubMedGoogle Scholar
- Guzman RE, Evans MG, Bove S, Morenko B, Kilgore K. Mono-iodoacetate-induced histologic changes in subchondral bone and articular cartilage of rat femorotibial joints: an animal model of osteoarthritis. Toxicol Pathol. 2003;31(6):619–24.View ArticlePubMedGoogle Scholar
- Janusz MJ, Little CB, King LE, Hookfin EB, Brown KK, Heitmeyer SA, et al. Detection of aggrecanase- and MMP-generated catabolic neoepitopes in the rat iodoacetate model of cartilage degeneration. Osteoarthr Cartil. 2004;12(9):720–8. doi:10.1016/j.joca.2004.06.004.View ArticlePubMedGoogle Scholar
- Gibon E, Ma T, Ren PG, Fritton K, Biswal S, Yao Z, et al. Selective inhibition of the MCP-1-CCR2 ligand-receptor axis decreases systemic trafficking of macrophages in the presence of UHMWPE particles. J Orthop Res. 2012;30(4):547–53. doi:10.1002/jor.21548.View ArticlePubMed CentralPubMedGoogle Scholar
- Lafeber FP, van Spil WE. Osteoarthritis year 2013 in review: biomarkers; reflecting before moving forward, one step at a time. Osteoarthr Cartil. 2013;21(10):1452–64. doi:10.1016/j.joca.2013.08.012.View ArticlePubMedGoogle Scholar
- Shurin GV, Yurkovetsky ZR, Chatta GS, Tourkova IL, Shurin MR, Lokshin AE. Dynamic alteration of soluble serum biomarkers in healthy aging. Cytokine. 2007;39(2):123–9. doi:10.1016/j.cyto.2007.06.006.View ArticlePubMedGoogle Scholar
- van Tuyl LH, Vlad SC, Felson DT, Wells G, Boers M. Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference. Arthritis Rheum. 2009;61(5):704–10. doi:10.1002/art.24392.View ArticlePubMed CentralPubMedGoogle Scholar
- Proudfoot AE. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol. 2002;2(2):106–15. doi:10.1038/nri722.View ArticlePubMedGoogle Scholar
- Onuffer JJ, Horuk R. Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Trends Pharmacol Sci. 2002;23(10):459–67.View ArticlePubMedGoogle Scholar
- Bove SE, Calcaterra SL, Brooker RM, Huber CM, Guzman RE, Juneau PL, et al. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthr Cartil. 2003;11(11):821–30.View ArticlePubMedGoogle Scholar